Bio-Techne Sets Sept. 23 Vote on $73-Per-Share Merck KGaA Buyout

What happened

Bio-Techne Corporation filed a definitive proxy statement with the SEC on August 20, 2026, setting a special meeting of shareholders for September 23, 2026 at 9:00 a.m. Eastern Time, to be held as a virtual meeting via live webcast.

The filing states that on June 25, 2026, Bio-Techne entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany, and EMD Holdings NewCo, Inc., a Minnesota corporation and wholly-owned subsidiary of Merck KGaA created to carry out the deal. Under the agreement, that subsidiary will merge into Bio-Techne, and Bio-Techne will continue as the surviving corporation and a wholly-owned subsidiary of Merck KGaA.

At the effective time of the merger, each outstanding share of Bio-Techne common stock will be converted into the right to receive $73.00 in cash, without interest, subject to required tax withholdings, with limited exceptions described in the filing for restricted shares, treasury and affiliated shares, and shares held by shareholders who properly exercise dissenters' rights under Minnesota law.

Shareholders of record at 5:00 p.m. Eastern Time on August 11, 2026 are entitled to notice of and to vote at the meeting. Bio-Techne's board unanimously approved the merger agreement and recommends shareholders vote "FOR" the merger proposal, "FOR" an advisory proposal on merger-related executive compensation, and "FOR" a proposal to adjourn the meeting if more votes are needed.

Bio-Techne shares closed at $72.285 on the event date, down 0.03% from the prior close of $72.31.

The filing does not describe why Merck KGaA is acquiring Bio-Techne; a background of the merger is referenced in the proxy but the excerpt reviewed here does not include it.

The company

Bio-Techne is a Minneapolis, Minnesota-based company classified in SEC filings under Biological Products (No Diagnostic Substances). It is the registrant named on the proxy statement, headquartered at 614 McKinley Place N.E., Minneapolis, Minnesota 55413.

The proxy letter is signed by Robert V. Baumgartner, Chairman of the Board, and Kim Kelderman, President, Chief Executive Officer and Director.

What this means

The document is a DEFM14A, a definitive merger proxy statement under Schedule 14A of the Securities Exchange Act of 1934. A proxy statement is the package a public company must send shareholders before a vote; the "definitive" label means it is the final version, as opposed to the preliminary "PRE" version filed earlier. It satisfies the company's obligation under Section 14(a) to give shareholders full information before they vote on their behalf. Because the vote concerns a merger, the proxy includes the merger agreement itself as Annex A.

A merger agreement is the contract that sets the terms of the deal. Here the structure is a two-step: Merck KGaA formed a new subsidiary, Merger Sub, solely to merge into Bio-Techne. That reverse-triangular structure means Bio-Techne's corporate existence continues, but its shares stop trading and it becomes a subsidiary of Merck KGaA. The $73.00 per share is cash consideration, so shareholders are being cashed out rather than receiving stock in the acquirer.

The vote requirement is specific: the merger cannot close unless holders of a majority of the voting power of outstanding Bio-Techne common stock entitled to vote approve the merger agreement. The filing warns that failing to vote has the same effect as voting against, and that shares held in street name cannot be voted by a bank, broker or nominee without the holder's instructions. That is why the notice tells shareholders their vote matters even if they own few shares.

The filing lists several regulatory approvals and other closing conditions, and describes termination fees payable in certain circumstances, but the excerpt available here does not specify their amounts or which regulators must clear the deal. It also includes a non-binding compensation advisory proposal, sometimes called a "golden parachute" vote, which lets shareholders express an opinion on payments to named executive officers tied to the merger. That vote does not bind the company or change the deal terms.

The next scheduled step is the September 23, 2026 special meeting. If the merger agreement is approved and the remaining conditions in the filing are satisfied, the merger would close and each share would be exchanged for $73.00 in cash. The filing does not set a closing date.